Response to letter from Mishra and Singh
Open Access
- 13 August 2022
- journal article
- letter
- Published by Elsevier BV in Journal of Hepatology
- Vol. 77 (5), 1452-1453
- https://doi.org/10.1016/j.jhep.2022.07.024
Abstract
No abstract availableFunding Information
- Cidara Therapeutics
- GlaxoSmithKline
- CymaBay Therapeutics
- Novartis
- Arrien Pharmaceuticals
- Eli Lilly and Company
- Gilead Sciences
This publication has 6 references indexed in Scilit:
- Seladelpar in patients with primary biliary cholangitis: Need a closer look!Journal of Hepatology, 2022
- A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitisJournal of Hepatology, 2022
- Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitisLiver International, 2021
- A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary CholangitisThe New England Journal of Medicine, 2016
- Primary Biliary Cirrhosis is More Severe in Overweight PatientsJournal of Clinical Gastroenterology, 2013
- Assessment of Liver Fibrosis and Steatosis in PBC With FibroScan, MRI, MR-spectroscopy, and Serum MarkersJournal of Clinical Gastroenterology, 2010